BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$71.41 USD
+0.27 (0.38%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $71.42 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 501 - 520 ( 822 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 15
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 8
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
We Anticipate In-Line Q4/YE:15 Financials; Reiterate Neutral and $117 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
February and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 1This report contains brief updates on the following: SRPT, RGLS, BMRN, CBYL, CLDX, EPRS, LXRX, PCRX, PRTA, PTCT, RPTP, TTPH, RARE, VTAE, ICPT, CERU, FCSC, GBT, TSRO, TRVN, IRWD, MRTX, DNAI, XNCR. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
We Have Removed Kyndrisa from Our Model Due to the Complete Response Letter and Toxicities; Reiterate NEUTRAL but Reducing Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 11th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
On the January DMD Docket - A Drisa Decision and Eteplirsen Panel
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - January and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 21st
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L